{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:33:21Z","timestamp":1787506401240,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":829,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Tumor-treating fields (TTFields) are a noninvasive antimitotic cancer treatment consisting of low-intensity alternating electric fields delivered to the tumor or tumor bed via externally applied transducer arrays. In multiple in vitro and in vivo cancer cell lines, TTFields therapy inhibits cell proliferation, disrupts cell division, interferes with cell migration and invasion, and reduces DNA repair. Human trials in patients with primary glioblastoma showed an improvement in overall survival, and trials in patients with unresectable malignant pleural mesothelioma showed favorable outcomes compared with historical control. This led to U.S. Food and Drug Administration approval in both clinical situations, paving the way for development of trials investigating TTFields in other malignancies. Although these trials are ongoing, the existing evidence suggests that TTFields have activity outside of neuro-oncology, and further study into the mechanism of action and clinical activity is required. In addition, because TTFields are a previously unrecognized antimitotic therapy with a unique mode of delivery, the oncological community must address obstacles to widespread patient and provider acceptance. TTFields will likely join surgery, systemic therapy, and radiation therapy as a component of multimodality management of patients with solid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Tumor-treating fields (TTFields) exhibit a broad range of antitumor activities. Clinically, they improve overall survival for patients with newly diagnosed glioblastoma. The emergence of TTFields has changed the treatment regimen for glioblastoma. Clinicians need to understand the practical issues surrounding its use in the multidisciplinary management of patients with glioblastoma. With ongoing clinical trials, TTFields likely will become another treatment modality for solid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0603","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T14:49:05Z","timestamp":1566571745000},"page":"e1426-e1436","source":"Crossref","is-referenced-by-count":28,"title":["Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies"],"prefix":"10.1093","volume":"24","author":[{"given":"Yuefeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, West Cancer Center and Research Institute, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, West Cancer Center and Research Institute, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Ballo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, West Cancer Center and Research Institute, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"key":"2021122508154220900_onco13034-bib-0001","first-page":"333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas","volume":"49","author":"Walker","year":"1978","journal-title":"A cooperative clinical trial. J Neurosurg"},{"key":"2021122508154220900_onco13034-bib-0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122508154220900_onco13034-bib-0003","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"2021122508154220900_onco13034-bib-0004","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"2021122508154220900_onco13034-bib-0005","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122508154220900_onco13034-bib-0006","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci Rep"},{"key":"2021122508154220900_onco13034-bib-0007","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2021122508154220900_onco13034-bib-0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/147323001204000109","article-title":"Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms","volume":"40","author":"Chen","year":"2012","journal-title":"J Int Med Res"},{"key":"2021122508154220900_onco13034-bib-0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","article-title":"Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields","volume":"14","author":"Giladi","year":"2014","journal-title":"Pancreatology"},{"key":"2021122508154220900_onco13034-bib-0010","doi-asserted-by":"crossref","first-page":"65125","DOI":"10.18632\/oncotarget.11372","article-title":"Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"2021122508154220900_onco13034-bib-0011","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/ijc.30406","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo","volume":"139","author":"Voloshin","year":"2016","journal-title":"Int J Cancer"},{"key":"2021122508154220900_onco13034-bib-0012","author":"Michelhaugh","year":"2017"},{"key":"2021122508154220900_onco13034-bib-0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125269","article-title":"Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit","volume":"10","author":"Gera","year":"2015","journal-title":"PLoS One"},{"key":"2021122508154220900_onco13034-bib-0014","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.171","article-title":"Biological activity of tumor-treating fields in preclinical glioma models","volume":"8","author":"Silginer","year":"2017","journal-title":"Cell Death Dis"},{"key":"2021122508154220900_onco13034-bib-0015","author":"Garcia-Carracedo","year":"2017"},{"key":"2021122508154220900_onco13034-bib-0016","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1755-148X.2010.00704.x","article-title":"Apoptosis initiation and angiogenesis inhibition: Melanoma targets for nanosecond pulsed electric fields","volume":"23","author":"Chen","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021122508154220900_onco13034-bib-0017","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.136","article-title":"Tumor treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines","volume":"8","author":"Karanam","year":"2017","journal-title":"Cell Death Dis"},{"issue":"suppl 6","key":"2021122508154220900_onco13034-bib-0018","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","volume":"41","author":"Giladi","year":"2014","journal-title":"Semin Oncol"},{"key":"2021122508154220900_onco13034-bib-0019","doi-asserted-by":"crossref","first-page":"62267","DOI":"10.18632\/oncotarget.11407","article-title":"Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"2021122508154220900_onco13034-bib-0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","article-title":"Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells","volume":"12","author":"Giladi","year":"2017","journal-title":"Radiat Oncol"},{"key":"2021122508154220900_onco13034-bib-0021","author":"Voloshin","year":"2017"},{"key":"2021122508154220900_onco13034-bib-0022","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","article-title":"Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs","volume":"26","author":"Kirson","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"2021122508154220900_onco13034-bib-0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1477-7819-10-220","article-title":"Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields","volume":"10","author":"Rulseh","year":"2012","journal-title":"World J Surg Oncol"},{"key":"2021122508154220900_onco13034-bib-0024","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomized phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"issue":"suppl 6","key":"2021122508154220900_onco13034-bib-0025","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1053\/j.seminoncol.2014.09.008","article-title":"EF-11 Investigators. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A system versus best physician's choice chemotherapy","volume":"41","author":"Kanner","year":"2014","journal-title":"Semin Oncol"},{"key":"2021122508154220900_onco13034-bib-0026","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","article-title":"Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A large-scale numerical simulation-based analysis of data from the phase 3 EF-14 randomized trial","volume":"104","author":"Ballo","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 6","key":"2021122508154220900_onco13034-bib-0027","article-title":"PriCoTTF: A phase I\/II trial of tumor treating fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma","volume":"20","author":"Glas","year":"2018","journal-title":"Neuro Oncol"},{"issue":"suppl 15","key":"2021122508154220900_onco13034-bib-0028","article-title":"A phase II study of tumor treating fields (TTF) in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC): Updated survival results","volume":"29","author":"Pless","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122508154220900_onco13034-bib-0029","author":"Weinberg","year":"2017"},{"key":"2021122508154220900_onco13034-bib-0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2021122508154220900_onco13034-bib-0031","author":"Benavides","year":"2017"},{"key":"2021122508154220900_onco13034-bib-0032","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"2021122508154220900_onco13034-bib-0033","author":"Ceresoli","year":"2018"},{"key":"2021122508154220900_onco13034-bib-0034","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: A secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol"},{"issue":"suppl 6","key":"2021122508154220900_onco13034-bib-0035","article-title":"The cost effectiveness of tumor treating fields treatment for patients with newly diagnosed glioblastoma based on the EF-14 trial","volume":"20","author":"Guzauskas","year":"2018","journal-title":"Neuro Oncol"},{"key":"2021122508154220900_onco13034-bib-0036","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1088\/0031-9155\/60\/18\/7339","article-title":"The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: A computational study","volume":"60","author":"Wenger","year":"2015","journal-title":"Phys Med Biol"},{"key":"2021122508154220900_onco13034-bib-0037","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1088\/0031-9155\/59\/15\/4137","article-title":"Predicting the electric field distribution in the brain for the treatment of glioblastoma","volume":"59","author":"Miranda","year":"2014","journal-title":"Phys Med Biol"},{"key":"2021122508154220900_onco13034-bib-0038","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/cam4.519","article-title":"Computed modeling of alternating electric fields therapy for recurrent glioblastoma","volume":"4","author":"Lok","year":"2015","journal-title":"Cancer Med"},{"key":"2021122508154220900_onco13034-bib-0039","first-page":"2555","article-title":"Modeling tumor treating fields (TTFields) application within a realistic human head model","volume":"2015","author":"Wenger","year":"2015","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"2021122508154220900_onco13034-bib-0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2015.11.042","article-title":"Improving tumor treating fields treatment efficacy in patients with glioblastoma using personalized array layouts","volume":"94","author":"Wenger","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122508154220900_onco13034-bib-0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13014-018-0976-3","article-title":"Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - A planning study","volume":"13","author":"Straube","year":"2018","journal-title":"Radiat Oncol"},{"key":"2021122508154220900_onco13034-bib-0042","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12957-015-0722-3","article-title":"NovoTTF-100A System (tumor treating fields) transducer array layout planning for glioblastoma: A NovoTAL system user study","volume":"13","author":"Chaudhry","year":"2015","journal-title":"World J Surg Oncol"},{"key":"2021122508154220900_onco13034-bib-0043","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/cns-2016-0032","article-title":"A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma","volume":"6","author":"Trusheim","year":"2016","journal-title":"CNS Oncol"},{"key":"2021122508154220900_onco13034-bib-0044","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cam4.210","article-title":"Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma","volume":"3","author":"Wong","year":"2014","journal-title":"Cancer Med"},{"key":"2021122508154220900_onco13034-bib-0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000250","article-title":"Tumor treating fields: A new standard treatment for glioblastoma?","volume":"28","author":"Taillibert","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"2021122508154220900_onco13034-bib-0046","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/neuonc\/nox014","article-title":"NovoTTF: Where to go from here?","volume":"19","author":"Cloughesy","year":"2017","journal-title":"Neuro Oncol"},{"key":"2021122508154220900_onco13034-bib-0047","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.2015.16701","article-title":"Alternating electric fields for the treatment of glioblastoma","volume":"314","author":"Sampson","year":"2015","journal-title":"JAMA"},{"key":"2021122508154220900_onco13034-bib-0048","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: A potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0603","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/e1426\/41918580\/oncolo_24_12_e1426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/e1426\/41918580\/oncolo_24_12_e1426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T03:16:48Z","timestamp":1640402208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/12\/e1426\/6439509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,23]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,8,23]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0603","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,8,23]]}}}